Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
NCT ID: NCT00223951
Last Updated: 2015-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
900 participants
INTERVENTIONAL
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
NCT00244543
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
NCT00241319
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
NCT00364091
A Six-Week Safety Study of an Investigational Ophthalmic Solution
NCT01698814
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis
NCT00445874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
R89674 (generic name not yet established)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
Exclusion Criteria
3 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vistakon Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jack V Greiner, OD, DO, PhD
Role: PRINCIPAL_INVESTIGATOR
Ophthalmic Research Associates, North Andover, MA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Bel Air, Maryland, United States
North Andover, Massachusetts, United States
Las Vegas, Nevada, United States
Charlotte, North Carolina, United States
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-003-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.